Scholarlink

<p>Purpose: Scars may lead to pain, pruritus, functional impairment, and cosmetic concern despite standard therapies. Photobiomodulation (PBM) delivered by light-emitting-diode (LED) or low-level laser therapy (LLLT) has emerged as a non-invasive option to modulate scar remodeling. However, available data derives from small, heterogenous studies. This scoping review evaluates whether red and near-infrared PBM improves clinical outcomes in burn, hypertrophic, and post-surgical scars and summarizes treatment parameters used. Methods: PubMed, Embase, and MEDLINE were searched through October 2025 for randomized or prospective clinical studies in which red (633-670nm) or near-infrared (808-830nm) LED or LLLT was used as monotherapy or where its contribution could be independently assessed. Seven studies (n=297) met inclusion criteria. Data on scar type, wavelength, fluence, regimen, outcomes, and adverse events were extracted. Results: Red LED improved VSS scores, pigmentation, and thickness in pediatric and adult burn scars, with greater benefits observed in scars &lt; 12 months. In post-surgical scars, red LED reduced induration and improved POSAS scores, with a biphasic dose-response favoring moderate fluence levels. Near-infrared PBM improved color and elasticity in hypertrophic scars and reduced thickness, malleability, pain, and pruritus following hernia repair, thyroidectomy, and blepharoplasty. Across studies, PBM was well tolerated; transient erythema and warmth were most common, with rare blistering at higher fluences. Conclusion: Red and near-infrared PBM appears to be a safe, non-invasive adjunct to standard scar management, particularly for early burn and post-operative scars. Larger controlled trials are needed to define optimal wavelength, fluence, timing, and treatment parameters across diverse scar phenotypes and skin phototypes. Clinical Trial Registration: Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Red and near-infrared photobiomodulation for burn, hypertrophic, and post-surgical scars: a scoping review of clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月24日

查看全文
  • Simonetta I. Gaumond,
  • Emilee M. Dreifus,
  • Amisha Mittal,
  • Ariel E. Eber

摘要

Purpose: Scars may lead to pain, pruritus, functional impairment, and cosmetic concern despite standard therapies. Photobiomodulation (PBM) delivered by light-emitting-diode (LED) or low-level laser therapy (LLLT) has emerged as a non-invasive option to modulate scar remodeling. However, available data derives from small, heterogenous studies. This scoping review evaluates whether red and near-infrared PBM improves clinical outcomes in burn, hypertrophic, and post-surgical scars and summarizes treatment parameters used. Methods: PubMed, Embase, and MEDLINE were searched through October 2025 for randomized or prospective clinical studies in which red (633-670nm) or near-infrared (808-830nm) LED or LLLT was used as monotherapy or where its contribution could be independently assessed. Seven studies (n=297) met inclusion criteria. Data on scar type, wavelength, fluence, regimen, outcomes, and adverse events were extracted. Results: Red LED improved VSS scores, pigmentation, and thickness in pediatric and adult burn scars, with greater benefits observed in scars < 12 months. In post-surgical scars, red LED reduced induration and improved POSAS scores, with a biphasic dose-response favoring moderate fluence levels. Near-infrared PBM improved color and elasticity in hypertrophic scars and reduced thickness, malleability, pain, and pruritus following hernia repair, thyroidectomy, and blepharoplasty. Across studies, PBM was well tolerated; transient erythema and warmth were most common, with rare blistering at higher fluences. Conclusion: Red and near-infrared PBM appears to be a safe, non-invasive adjunct to standard scar management, particularly for early burn and post-operative scars. Larger controlled trials are needed to define optimal wavelength, fluence, timing, and treatment parameters across diverse scar phenotypes and skin phototypes. Clinical Trial Registration: Not applicable.